Marketed under the name Intelence, the drug was reportedly effective in increasing the amount of white blood cells in the patient's blood, thereby upping the chances of fighting infections. Intelence was said to benefit patients who have been unresponsive to other anti-HIV drugs.
A study on the effectiveness of the drug proved that compared to other drugs, patients showed a significant decrease in their blood's HIV levels, reported the Voice of America.
Approval applications for Intelence have also been submitted to the European Agency for the Evaluation of Medicinal Products, as well as to similar health authorities in Canada, Russia, Switzerland and Australia.
The drug, however, is yet to be tested on pregnant women.
Dr. Richard Haubrich of the University of California, who was part of the study conducted on Intelence, explained that in the case of other anti-HIV drugs, resistance to one nucleoside reverse transcriptase inhibitor means resistance to all others.
MarketWatch reported that Intelence would be available in the U.S. for wholesale within one week.
